UK, first country to approve Modern bivalent vaccine against covid-19

The United Kingdom became this Monday the first country to approve the bivalent vaccine American Moderna, which was developed to attack the original covid-19 virus and the new omicron variantas reported by the Medicines and Health Care Regulatory Agency (MHRA).

With this decision, the vaccine is expected to be used as a booster next fall, although the number of doses available is currently unknown.

The health authorities had already indicated that, from next September, a reinforcement shot people over 50 and people who are in the highest risk groups.

The initial vaccines used during the pandemic were developed to fight the original form of the virus that emerged in Wuhan, China, in late 2019, but has since the virus has changed as new variants emerge that can evade the immune system, which has caused outbreaks of the disease in many countries.

With this bivalent vaccine, it is expected that only a single injection will be required in adults once a year.

With this bivalent vaccine, it is expected that only a single injection will be required in adults once a year.

Known as mRNA-1273.214, the dose is an updated version of the Modern vaccine that is already given as a first, second and booster dose, and is now an approved dose in the UK that targets two strains of the virus.

Similar and mild side effects

According to the MHRA, the vaccine’s side effects are the same as those seen with Moderna’s original booster dose and were generally mild.

The Executive Director of the MHRA, June Rainedescribed the new reinforcement as “a sharp tool in our arsenal” to protect the UK against Covid-19.

Read Also:  Automating Reporting And Analytics Processes

“I am pleased to announce the approval of the Moderna bivalent booster vaccine” to “provide a strong immune response against the BA.1 omicron variant as well as the original 2020 strain,” added Raine.

Moderna’s medical director, Paul Burtonsaid the new injection can increase a person’s antibodies to levels so high that they may only be needed annually.

The virus is unlikely to sit still and immunity targeted to the omicron could push the virus down other evolutionary paths.

Jonathan Ball, a virologist at the University of Nottingham

experts say

In statements to SMC UKthe teacher Jonathan BallProfessor of Molecular Virology at the University of Nottingham, highlights that “the first data indicate that the new Moderna vaccine, targeting two different types of protein spike of the coronavirus, works best against the fresh-looking omicron variants. These variants were better able to escape antibodies generated by infection or vaccination than the previous ones, so [la nueva vacuna] It should provide better protection.”

However, Ball opines that “the virus is unlikely to sit still and immunity targeted to the omicron could push the virus down other evolutionary paths, in which case we will be like the Red Queen in Alice and the Looking Glass, having to keep running to stay on track.” same place. That said, unless there is a major change in the virus, immunity will continue to protect against the vast majority of serious illnesses caused by emerging variants, which is why it is important to be vaccinated or boosted, especially if you are vulnerable.”

Recent Articles

Related News

Leave A Reply

Please enter your comment!
Please enter your name here